abstract |
Provided in the present invention is a new-type pan-RAF kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite, or prodrug thereof. Also provided in the present invention are a use and method of the compound of formula (I) for preventing or treating disorders related to RAF and/or RAS kinase activity. |